Arrowhead Pharmaceuticals: Important Catalysts And Some Challenges Ahead

Core Insights - Arrowhead Pharmaceuticals (ARWR) has significant upcoming events, including the PDUFA date for plozasiran for treating familiar chylomicronemia syndrome (FCS) and the release of fiscal Q4 2025 results [2] Company Developments - The PDUFA date for plozasiran is scheduled for tomorrow, indicating a critical regulatory milestone for Arrowhead Pharmaceuticals [2] - Fiscal Q4 2025 results are anticipated next week, which may provide insights into the company's financial performance and future outlook [2] Investment Focus - The Growth Stock Forum, led by a former stockbroker, emphasizes identifying growth and biotech stocks with substantial growth potential, focusing on risk-adjusted returns [2]